Early promise for novel breast cancer immunotherapy
With potential “groundbreaking” results, the immunotherapy could alter the need for breast cancer patients to undertake chemotherapy, trial investigators suggest.
List view / Grid view
With potential “groundbreaking” results, the immunotherapy could alter the need for breast cancer patients to undertake chemotherapy, trial investigators suggest.
This article highlights some of the key regulatory approvals granted in May and June in the EU and US so far this year, including for oligonucleotide and biologic therapies.
A novel ultrasound technique opened the blood-brain barrier to successfully deliver chemotherapy to glioblastoma patients in a first-in-human trial.
An interim analysis of a Phase III trial showed pembrolizumab plus chemotherapy significantly improved survival in endometrial cancer.
4 November 2022 | By
Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? Colin Freund, Chief Executive Officer of Modra Pharmaceuticals, reveals the benefits of this emerging generation of anticancer treatment.
EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
The FDA has given small molecules APG-115 and APG-1252, two cancer treatments, Orphan Drug Designation.
Polyelectrolyte multilayers (PEMs) are promising drug carriers with potential applications in the delivery of poorly soluble drugs. In this article, Sumayah Abdul-Jabbar and Paul Royall discuss the approaches for PEM construction and drug release and detail several applications of multilayered particles in therapeutics.
A new drug delivery system disguises chemo-therapeutics as fat in order to destroy tumours.
Chemotherapy drugs commonly used in breast cancer leads to a decrease in muscle mitochondria, and could result in fatigue after treatment...